Skip to main content
Image coming soon

GEN1797 AI and Automation Leadership for Drug Development Executives

$201.00
Adding to cart… The item has been added

The Executive Diagnostic and Governance Toolkit

AI and Automation Leadership for Drug Development Executives

Score your own function red, amber or green, find out which part is weakest, and walk into the next budget round able to defend what you want to fix. Built for leaders reviewing deciding what to adopt, in what order, and defending that choice when the budget round asks why this and not that.

$199 one-time
30-day money-back guarantee Verified against latest insights, updated access provided within 24h

Each order is checked and updated against the latest insights before delivery. That is why access takes up to 24 hours rather than being instant.

What you walk out with
A scored, ranked picture of your own function, and a defensible answer to what to fix first.
1 You stop guessing where you stand.
You finish with a score, not an opinion: every part of your function rated red, amber or green, with the weakest ranked first. Evidence: a Quick Scan for the shape of it, then seven domain assessments of 30 scored questions each, 210 in all, rolled into one scorecard, plus a maturity radar and a current-versus-target gap analysis.
2 You can defend the decision.
You walk into the budget round with the gap named, the owner named and done defined, instead of a case built on instinct. Evidence: project charter, scope statement, RACI, requirements traceability and work breakdown structure, pre-filled in your domain's language.
3 The work actually moves.
The month after the decision is already built, so nothing stalls waiting for someone to design a form. Evidence: more than 60 project templates across all five PMBOK process groups, plus runbooks, SOPs, a KPI framework, audit checklists and a risk matrix. 55 to 65 files in total.
4 You use it the day it lands.
No blank templates to interpret. Every workbook opens with what it is, who uses it, when, how, a 1 to 5 scoring guide, what good looks like, and a worked example you delete and type over.
The Quick Scan is one sitting. You will know your weakest area before the day is out.
Nothing in it is generic project management: the build rejects any file that could belong to another course. Updated after you enrol, so it reflects where the work stands now. The 144-chapter course is included behind it, for the parts you want to go deeper on.
You’re drowning in AI promises while your team struggles to prioritize what actually moves the needle.

The situation this is built for

Every quarter, new AI capabilities emerge that claim to accelerate drug discovery, especially in predicting novel molecular pathways. You’re expected to adopt the right ones—but no one gives you a framework to assess what’s real, what’s ready, and what’s worth the investment. You end up choosing reactively, then defending those choices under budget scrutiny. The result? Missed opportunities, eroded trust, and a team pulled in too many directions.

Who this is for

A senior leader who owns the AI and automation function in a biopharmaceutical organization, responsible for aligning technical capabilities with strategic drug development goals and justifying investment decisions to executives and finance committees.

Who this is not for

This is not for data scientists building models, technical AI researchers, or procurement managers evaluating vendor contracts. It is not for those seeking a technical deep dive into machine learning architectures or open-source tooling.

What you walk away with

  • A clear, defensible assessment of your current AI and automation maturity
  • A prioritized roadmap aligned with first-in-class drug development objectives
  • Stakeholder alignment on AI adoption sequence and investment thresholds
  • Board-ready documentation for AI investment decisions
  • A repeatable process for evaluating new AI capabilities as they emerge

How this maps to your situation

  • Assessing where your AI capabilities stand today
  • Prioritizing what to adopt and in what order
  • Defending those choices to executives and finance
  • Building a sustainable process for future decisions

Before vs. after

Before
Overwhelmed by competing AI claims, reacting to new capabilities without a framework, struggling to justify choices to budget committees.
After
Confidently assessing, prioritizing, and defending AI adoption decisions with a clear, repeatable process aligned to drug development outcomes.

What's included with your purchase

  • 12 modules with 12 chapters each (144 chapters)
  • Downloadable templates and worked examples for every module
  • Hand-built implementation playbook delivered alongside course access
  • 30-day money-back guarantee

Delivery and format

  • Course and learning environment access provisioned within 24 hours of purchase
  • Hand-built implementation playbook delivered alongside course access

Format: Text-based modules and chapters in the Art of Service learning environment, plus downloadable templates and worked examples for every chapter, plus the hand-built implementation playbook delivered alongside course access.

Time investment: Approximately 8 hours per module, designed to be completed at your pace with practical exercises integrated into real work contexts.

If nothing changes
Without a structured approach, AI adoption becomes reactive and fragmented, leading to wasted investment, eroded stakeholder trust, and missed opportunities to deliver first-in-class therapies ahead of competitors.

How this compares to the alternatives

Unlike vendor-led training or academic courses, this program focuses exclusively on the leadership decisions behind AI adoption—what to prioritize, when to invest, and how to align teams—without promoting any specific tool or technology.

Also included: the full course, for when you want the reasoning behind a finding (12 modules, 144 chapters)

Depth reference. The diagnostic and the templates stand on their own; this is what to read when you want the reasoning behind a finding.

Module 1. Defining the Scope of AI in Drug Development
Establish a clear boundary for what AI and automation encompasses in your function, avoiding scope creep and misaligned expectations.
12 chapters in this module
  1. Identifying the core responsibilities of AI leadership in drug discovery
  2. Mapping AI use cases to stages of drug development
  3. Distinguishing between automation and predictive AI capabilities
  4. Assessing the impact of AI on clinical trial design decisions
  5. Defining success metrics for AI-enabled drug discovery
  6. Recognizing the limitations of current AI in molecular modeling
  7. Aligning AI scope with regulatory expectations for innovation
  8. Documenting assumptions behind AI adoption priorities
  9. Clarifying ownership of AI outcomes across functional teams
  10. Establishing decision rights for AI capability investments
  11. Integrating AI scope into portfolio review meetings
  12. Tracking shifts in AI scope due to external breakthroughs
Module 2. Assessing Current AI Capabilities
Conduct a rigorous audit of existing tools, models, and workflows to determine actual maturity and readiness for scale.
12 chapters in this module
  1. Inventorying all active AI and automation initiatives
  2. Evaluating model performance against historical benchmarks
  3. Auditing data quality inputs for predictive drug models
  4. Assessing integration depth with electronic lab notebooks
  5. Measuring team proficiency with AI interpretation tools
  6. Reviewing AI model validation processes for compliance
  7. Identifying redundant or overlapping AI capabilities
  8. Documenting technical debt in legacy automation systems
  9. Benchmarking internal AI outputs against industry standards
  10. Tracking model decay rates in target prediction systems
  11. Assessing reproducibility of AI-driven discovery results
  12. Classifying AI capabilities by development lifecycle stage
Module 3. Evaluating AI Readiness Across Functions
Determine organizational preparedness for AI adoption beyond the technical layer, including culture, skills, and governance.
12 chapters in this module
  1. Assessing data accessibility for cross-functional AI teams
  2. Measuring leadership understanding of AI limitations
  3. Evaluating change readiness in medicinal chemistry teams
  4. Identifying skill gaps in AI-assisted target identification
  5. Reviewing governance structures for AI model deployment
  6. Assessing ethical review processes for AI-generated hypotheses
  7. Measuring cross-functional collaboration on AI projects
  8. Evaluating documentation standards for AI model lineage
  9. Assessing risk tolerance for AI-driven decision making
  10. Identifying bottlenecks in AI model operationalization
  11. Reviewing training completeness for AI workflow adoption
  12. Assessing audit readiness for AI-influenced submissions
Module 4. Prioritizing AI Initiatives by Strategic Impact
Apply a structured framework to rank AI opportunities based on therapeutic area potential, resource needs, and speed to insight.
12 chapters in this module
  1. Ranking AI opportunities by probability of first-in-class success
  2. Estimating time savings in lead optimization cycles
  3. Assessing AI impact on preclinical attrition rates
  4. Prioritizing initiatives with highest regulatory pathway advantage
  5. Evaluating AI potential in rare disease target discovery
  6. Mapping AI initiatives to unmet medical needs
  7. Scoring AI projects by data availability and quality
  8. Assessing scalability of AI models across indications
  9. Estimating reduction in wet-lab validation burden
  10. Prioritizing AI for targets with high structural uncertainty
  11. Balancing exploratory AI with near-term deliverables
  12. Aligning AI prioritization with portfolio strategy reviews
Module 5. Building Defensible AI Investment Cases
Develop clear, evidence-based justifications for AI spending that resonate with finance and executive stakeholders.
12 chapters in this module
  1. Structuring AI investment requests for C-suite review
  2. Quantifying time-to-insight improvements from AI adoption
  3. Estimating cost avoidance from reduced compound failures
  4. Documenting assumptions behind AI efficiency claims
  5. Linking AI initiatives to pipeline milestone acceleration
  6. Creating comparatives between AI and traditional methods
  7. Forecasting headcount implications of AI automation
  8. Justifying AI spend using therapeutic area NPV
  9. Incorporating risk adjustments into AI ROI models
  10. Aligning AI budgets with R&D stage gate criteria
  11. Presenting AI trade-offs in portfolio prioritization forums
  12. Updating investment cases as AI performance evolves
Module 6. Designing AI Governance Structures
Create decision-making frameworks that ensure responsible, compliant, and effective AI deployment across drug development.
12 chapters in this module
  1. Defining approval thresholds for AI model deployment
  2. Establishing review cycles for AI-generated hypotheses
  3. Assigning accountability for AI model performance
  4. Creating escalation paths for AI prediction failures
  5. Documenting AI decision trails for regulatory audits
  6. Integrating AI governance into project steering committees
  7. Setting standards for AI model interpretability
  8. Requiring validation plans for extrapolative AI models
  9. Defining refresh cycles for AI training datasets
  10. Incorporating AI oversight into safety review boards
  11. Establishing version control for AI-driven target proposals
  12. Aligning AI governance with corporate risk appetite
Module 7. Integrating AI into Discovery Workflows
Embed AI capabilities into existing processes without disrupting critical path activities or team dynamics.
12 chapters in this module
  1. Mapping AI integration points in hit-to-lead workflows
  2. Designing handoff protocols between AI and lab teams
  3. Adapting medicinal chemistry review meetings for AI input
  4. Incorporating AI predictions into compound selection grids
  5. Adjusting project timelines for AI model development
  6. Creating feedback loops from wet-lab results to AI training
  7. Standardizing formats for AI hypothesis presentation
  8. Integrating AI alerts into project management dashboards
  9. Scheduling AI model retraining alongside clinical updates
  10. Aligning AI output frequency with team meeting rhythms
  11. Defining acceptance criteria for AI-proposed analogs
  12. Documenting workflow changes due to AI integration
Module 8. Scaling AI Across Therapeutic Areas
Develop strategies to expand AI adoption beyond pilot teams while maintaining quality and focus.
12 chapters in this module
  1. Assessing transferability of AI models across indications
  2. Planning phased rollout of AI capabilities by team
  3. Adapting AI tools for rare disease discovery contexts
  4. Managing AI resource allocation across portfolios
  5. Establishing centers of excellence for AI methods
  6. Creating templates for AI implementation in new areas
  7. Training leads to onboard teams to AI workflows
  8. Standardizing AI performance metrics across units
  9. Monitoring AI adoption equity across geographies
  10. Adjusting AI strategies for oncology versus immunology
  11. Evaluating AI scalability under pipeline expansion
  12. Tracking cross-therapeutic area AI knowledge transfer
Module 9. Measuring AI Performance and Value
Implement consistent, meaningful metrics that capture both scientific progress and operational efficiency.
12 chapters in this module
  1. Defining KPIs for AI-driven target identification
  2. Tracking AI contribution to compound nomination dates
  3. Measuring reduction in false positive rates with AI
  4. Assessing AI impact on medicinal chemistry cycles
  5. Calculating AI-enabled time savings in SAR analysis
  6. Monitoring model accuracy in toxicity prediction
  7. Evaluating AI influence on project go/no-go decisions
  8. Tracking AI adoption rates across research teams
  9. Measuring reproducibility of AI-generated insights
  10. Assessing AI model stability across data batches
  11. Quantifying reduction in experimental iterations
  12. Auditing AI performance against initial projections
Module 10. Communicating AI Progress to Stakeholders
Tailor updates for different audiences to maintain support and secure continued investment.
12 chapters in this module
  1. Structuring AI progress reports for executive reviews
  2. Translating AI model outputs for non-technical leaders
  3. Creating visualizations for AI impact on pipeline velocity
  4. Reporting AI milestones in development committee meetings
  5. Preparing AI updates for board-level R&D reviews
  6. Communicating AI limitations to clinical development teams
  7. Documenting AI learnings for portfolio strategy sessions
  8. Sharing AI success stories in internal newsletters
  9. Presenting AI trade-offs in cross-functional forums
  10. Updating finance partners on AI efficiency gains
  11. Aligning AI messaging with corporate innovation narratives
  12. Anticipating questions from audit and compliance teams
Module 11. Anticipating Future AI Capabilities
Stay ahead of emerging methods by building a forward-looking assessment process grounded in scientific plausibility.
12 chapters in this module
  1. Scanning for emerging AI applications in target discovery
  2. Evaluating plausibility of breakthrough AI claims
  3. Assessing readiness of generative models for scaffold design
  4. Monitoring advances in protein folding prediction systems
  5. Tracking integration of multi-omics data in AI models
  6. Evaluating AI potential in adaptive trial design
  7. Assessing timeline for autonomous lab integration
  8. Identifying inflection points in AI model accuracy
  9. Planning for AI-driven repurposing of legacy compounds
  10. Anticipating regulatory responses to AI-generated entities
  11. Evaluating AI readiness for tissue-specific delivery prediction
  12. Scanning for convergence between AI and CRISPR screening
Module 12. Sustaining AI Leadership Through Change
Institutionalize AI decision-making to maintain momentum and adaptability amid shifting scientific and organizational demands.
12 chapters in this module
  1. Embedding AI assessment into annual planning cycles
  2. Updating AI roadmaps in response to clinical data
  3. Revising governance models as AI capabilities mature
  4. Institutionalizing lessons from failed AI initiatives
  5. Maintaining AI prioritization discipline during crises
  6. Adapting AI strategies for new acquisition targets
  7. Refreshing AI training programs for new hires
  8. Evolving AI metrics with changing portfolio focus
  9. Sustaining executive engagement with AI progress
  10. Integrating AI leadership into talent development plans
  11. Preparing for AI workforce transformation shifts
  12. Closing the loop on AI implementation with retrospectives

Frequently asked

Who is this course designed for?
This course is for senior leaders who own the AI and automation function in drug development and are accountable for strategic adoption decisions.
How is the course structured?
12 modules, each containing 12 chapters (144 chapters total).
Does this course cover specific AI tools or platforms?
No. The course focuses on decision-making frameworks, prioritization methods, and governance practices, not technical implementation or vendor comparisons.
Will I receive practical resources with the course?
Yes. Every module includes downloadable templates and worked examples, and you receive a hand-built implementation playbook tailored to your context.
Can I apply this course to my current portfolio?
Yes. The course is designed to be applied directly to your existing responsibilities, with exercises that integrate into real-world decision cycles.
What formats do the templates come in?
The implementation playbook downloads as PDF and editable XLSX. The course reads in your learning environment and exports to PDF for offline use. The files are yours to keep.
Can I share this with my team?
The licence is per person. Team pricing opens from three seats: reply to the order confirmation with TEAM and we will set it up.
How quickly can I start?
The diagnostic is one sitting and the templates work straight out of the kit. Account access takes up to 24 hours rather than being instant, because every order is checked and updated against the latest sources before it is delivered.
$199 one-time. Approximately 8 hours per module, designed to be completed at your pace with practical exercises integrated into real work contexts..

Within 24 hours your account in the learning environment is provisioned and the tailored implementation playbook is delivered alongside it.

30-day money-back guarantee·Know your weakest area today·210 scored questions·Course included· Account access within 24 hours
30-day money-back guarantee, no questions asked.
Thousands of organisations have bought from The Art of Service since 2000.
!